the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
September 01, 2015 – The American Food and Drug Administration recently approved Evolocumab (Repatha) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. Evolocumab (Repatha), the second drug approved in a …
Evolocumab (Repatha) to treat certain patients with high cholesterol Read more »
August 01, 2015 – On July 24, 2015, the American Food and Drug Administration (FDA) approved Alirocumab (Praluent) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. …
May 22, 2015 – The European Medicines Agency (EMA) has recommended authorising Evolocumab (Repatha) as treatment to lower high levels of cholesterol in the blood of people who are unable to control their cholesterol despite taking optimal doses of statins …
Evolocumab (Repatha), a novel first-in-class treatment to lower cholesterol Read more »